Esperion to Be Acquired by ARCHIMED in $1.1 Billion Deal, Shares Jump 56%
ARCHIMED will acquire Esperion Therapeutics for $3.16 per share in cash plus contingent value rights, valuing the deal at up to $1.1 billion. Esperion shares surged 56% on the news.
Markets
